Behçet's disease (BD) is a multisystem inflammatory disorder currently classified as a vasculitis. Its etiopathogenesis is unclear, but environmental, genetic and autoimmune factors have been ...
PRINCETON, N.J., Aug. 18, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to ...
Please provide your email address to receive an email when new articles are posted on . The rare and complex Behcet’s disease is often misdiagnosed or undiagnosed, leading to significant, but ...
PRINCETON, N.J., July 31, 2025 /PRNewswire/ -- Soligenix, Inc. (SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat ...
PRINCETON, N.J., Feb. 8, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to ...
Phase 1 Clinical Trial Met All Primary and Secondary Endpoints and Demonstrated Positive Safety, Pharmacokinetics, and ...
LONDON--(BUSINESS WIRE)--Technavio has announced their latest pipeline analysis report on the Behcet's syndrome market. The report includes a detailed analysis of the pipeline molecules under ...
Behçet's disease is a complex, multisystem inflammatory disorder characterised by recurrent mucocutaneous lesions, ocular involvement, and vascular, neurological, and gastrointestinal manifestations.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback